RxDoctor Payments Data

Mack Arroliga, MD

Pain Medicine · Huntington, WVNPI 1669883351

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Medtronic at 34.3% of the total. Reporting peaked in 2019 at $1,543 and has fallen 83.6% since, to $253 in 2025.

$4,065in general payments, 2019–2025

Across 139 payments — averaging $29.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boston Scientific$1K
  • Abbott$446
  • Nevro Corp.$402
  • Si-bone, Inc.$152
  • Amgen$125
  • plus $465 from 10 others

What the payments were for

  • Food & beverage$4,065100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,065 in reported general payments places this provider in the 65th percentile of 35 pain medicine providers in West Virginia.

See all pain medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$49,193
Medicare patients
131
Services billed
507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate17$8,283
Fentanyl11$731
Oxycodone Hcl13$488
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$429
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$219
Gabapentin12$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$59$8,28317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 35 pain medicine providers in West Virginia.

Other pain medicine in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →